Why This Matters: 3. Suppression & The Hypocrisy of Regulation Regulatory Double Standard: Closing Argument: A Denial of Hope & Progress If immune dysfunction is a key factor in autism, and VDTP/GcMAF has demonstrated real potential in addressing it, then suppressing it is not just scientific negligence—it is a denial of hope for thousands of…

The Early Access to Medicines Scheme (EAMS) in the UK is designed to speed up patient access to promising new medicines that address serious or life-threatening conditions before full marketing authorization is granted. Since autism is a lifelong condition with significant unmet medical need, VDTP/GcMAF could be eligible if strong safety and efficacy data are…

The Promising Innovative Medicine (PIM) Designation is the first step in the UK’s Early Access to Medicines Scheme (EAMS). It is awarded by the Medicines and Healthcare products Regulatory Agency (MHRA) to recognize a new medicine with potential to address an unmet medical need. If VDTP/GcMAF is granted PIM status, it opens the door to…

Introduction Vitamin D-binding protein (VDBP) is a crucial glycoprotein with multiple physiological roles, including transporting vitamin D metabolites, scavenging actin, and modulating immune responses. While traditionally studied for its systemic effects, emerging evidence suggests that VDBP, when applied topically, can exert significant immunological benefits both on the skin and potentially throughout the body. Immune Activation…

At the heart of the Vitamin D-binding Protein (GcMAF/VDBP) controversy is not just a debate about supplement vs. medicine, but something far deeper—a battle over who controls immune function, whether human biology itself is being manipulated under the guise of regulation, and the legal consequences of restricting access to a naturally occurring immune protein. 1.…